7.5.4. trimodality bladder-preserving treatment. bladder preservation alternative rc generally reserved patients smaller solitary tumours, extensive multifocal cis, tumour-related hydronephrosis, good pre-treatment bladder function. trimodality bladder-preserving treatment also considered patients contraindication surgery, either relative absolute contraindication since factors determine fitness surgery chemoradiotherapy differ. trimodality therapy combines turb, chemotherapy rt. rationale combine turb rt achieve maximal local tumour control bladder adjacent nodes. addition radiosensitising chemotherapy radiosensitisers (mentioned below) aimed potentiation rt. micrometastases targeted platinum-based combination chemotherapy (for details see section 7.1). aim tmt preserve bladder qol without compromising oncological outcome. definitive contemporary data supporting benefit using neoadjuvant adjuvant chemotherapy combined chemoradiation. patient selection critical achieving good outcomes . whether node dissection performed tmt rc remains unclear . case tmt, two distinct patterns care emerge; treatment aimed patients fit cystectomy elect tmt refuse cystectomy, treatment aimed older, less fit, patients. former category, tmt presents selective bladder preservation case initial step radical turb much tumour possible resected. case appropriate patient selection (e.g., t2 tumours, cis) crucial . even case initial presumed complete resection, second tur suggested reveal tumour > 50% patients subsequently improves 5-year os case tmt . patients candidates cystectomy, less stringent criteria applied, extensive cis poor bladder function regarded relative contraindications. collaborative review described principles tmt . radiation, two schedules commonly used; historically within rtog split-course format interval cystoscopy single- phase treatment commonly used . conventional radiation schedule includes ebrt bladder limited pelvic lns initial dose 40-45 gy, boost whole bladder 50–54 gy tumour boost total dose 60–66 gy. boosting tumour, also reasonable whole bladder treated 59.4–66 gy. node-positive disease, consider boosting grossly involved nodes highest achievable dose violate normal tissue constraints. therefore, elective treatment lns (when node negative) optional take account patient comorbidities risks toxicity adjacent critical structures. reasonable radiation dosing alternative conventional fractionation treating bladder-only fields moderately hypofractionated ebrt 55 gy 20 fractions suggested non-inferior 64 gy 32 fractions terms invasive loco-regional control, os late toxicity meta-analysis individual patient data bc2001 bcon studies. different concurrent chemotherapy regimens used, evidence exists cisplatin mitomycin-c plus 5-fu . alternative regimens evaluated include: single agent gemcitabine , capecitabine hypoxia modification carbogen/nicotinamide . recently published phase ii rct, twice-a-day radiation plus 5-fu/cisplatin compared once-daily radiation plus gemcitabine . arms found result > 75% free distant metastases rates 3 years (78% 84%, respectively). therefore, good chemotherapy options non-cisplatin candidates 5-fu/mitomycin-c low-dose gemcitabine. five-year css os rates vary 50%–84% 36%–74%, respectively, salvage cystectomy rates 10–30% . successfully completed rcts comparing outcome tmt rc. bc2001 trial 10 year follow-up showed combined radiotherapy mitomycin c fluorouracil significantly improved locoregional control five year cystectomy rates non-significantly improved dfs, os dss compared radiotherapy alone shown studies . many reported series differing characteristics compared larger surgical series, typically median ages mid- to-late 60s compared mid-70s large rt series (reviewed james, et al. ). completed randomised trials, rc tmt compared systematic reviews, meta-analyses, large population-based studies multi-institutional propensity score matched weighted analyses . overall, balance, studies show similar oncological outcomes radical cystectomy trimodality therapy select patients muscle-invasive bladder cancer. results support trimodality therapy, setting multidisciplinary shared decision making, offered suitable candidates muscle-invasive bladder cancer patients significant comorbidities surgery option . another study reported difference survival outcomes cn+ patients treated surgery versus radical rt . boston group also reported experience 66 patients mixed histological subtypes treated tmt found similar complete response, os, dss salvage cystectomy rates uc . majority recurrences post-tmt non-invasive managed conservatively . contemporary series, salvage cystectomy required 10–15% patients treated tmt curative . current data suggest major late complication rates slightly higher remain acceptable salvage- vs. primary cystectomy . sub-analysis two rtog trials looked complete response (t0) near-complete response (ta tis) tmt . median follow-up 5.9 years 41/119 (35%) patients experienced bladder recurrence, fourteen required salvage cystectomy. difference complete near- complete responders. non-muscle-invasive bc recurrences complete response tmt reported 25% patients boston group, sometimes decade initial treatment . nmibc recurrence associated lower dss, although properly selected patients, intravesical bcg could avoid immediate salvage cystectomy. overall significant late pelvic (gi/genitourinary [gu]) toxicity rates tmt low qol good . combined analysis survivors four rtog trials median follow-up 5.4 years showed combined-modality therapy associated low rates late grade 3 toxicity (5.7% gu 1.9% gi). late grade 4 toxicities treatment-related deaths recorded . retrospective study showed qol good tmt domains better cystectomy, although prospective validations needed . one option reduce side effects tmt use imrt image-guided rt (igrt) . bladder-preserving tmt strategy requires close multidisciplinary cooperation . also highlighted canadian group . ontario 1994 2008 10% (370/3,759) patients cystectomy pre-operative radiation oncology consultation, high geographical variations. independent factors associated consultation included advanced age (p < 0.001), greater comorbidity (p < 0.001) earlier year diagnosis (p < 0.001). bladder-preserving tmt strategy also requires high level patient compliance. even patient shown clinical response tmt bladder-preserving strategy, bladder remains potential source recurrence, hence long-term life-long bladder monitoring essential patients counselled required. 7.5.4.1. summary evidence recommednations trimodality bladder-preserving treatment summary evidencelelong-term survival rates tmt bladder-preserving treatment comparable early cystectomy . contraindications tmt surgery considered.2combined chemotherapy radiotherapy effective radiotherapy alone bladder sparing treatment.1b recommendationsstrength ratingoffer surgical intervention trimodality bladder-preserving treatments (tmt) appropriate candidates primary curative therapeutic approaches since effective radiotherapy alone.strongadvise patients candidates tmt mutlidisciplinary setting including urologists, medical oncologists radiation oncologists concerning benfits harms tmt.strongoffer tmt alternative selected, well-informed compliant patients, especially radical cystectomy option acceptable.strongadvise patients candidates tmt life-long bladder monitoring essential.strong 7.5.4.2. eau-esmo consensus statements management advanced- variant bladder cancer * consensus statementcandidates curative treatment, cystectomy bladder preservation, clinically assessed least oncologist, urologist, radiation oncologist (in case adjuvant radiotherapy bladder preservation considered) neutral hcp specialist nurse.an important determinant patient eligibility case bladder-preserving treatment absence carcinoma situ.an important determinant patient eligibility case bladder-preserving treatment absence presence hydronephrosis.when assessing patient eligibility bladder preservation, likelihood successful debulking surgery taken consideration (optimal debulking).in case bladder preservation radiotherapy, combination radiosensitiser always recommended improve clinical outcomes, cisplatin, 5-fu/mmc, carbogen/nicotinamide gemcitabine.radiotherapy bladder preservation performed imrt igrt reduce side effects.dose escalation standard radical doses primary site case bladder preservation, either imrt brachytherapy, recommended. *only statements met priori consensus threshold across three stakeholder groups listed (defined > 70% agreement < 15% disagreement, vice versa).hcp = healthcare professional; igrt = image-guided radiotherapy; imrt = intensity-modulated radiotherapy;5fu = 5-fluorouracil; mmc = mitomycin-c.